These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8980158)

  • 21. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners.
    Davies JS; Obuobie K; Smith J; Rees DA; Furlong A; Davies N; Evans LM; Scanlon MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):295-303. PubMed ID: 10718827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition.
    Jørgensen JO; Vahl N; Hansen TB; Thuesen L; Hagen C; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):681-8. PubMed ID: 9039333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
    Sverrisdóttir YB; Elam M; Caidahl K; Söderling AS; Herlitz H; Johannsson G
    J Hypertens; 2003 Oct; 21(10):1905-14. PubMed ID: 14508197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone.
    Ellis KJ; Lee PD; Pivarnik JM; Bukar JG; Gesundheit N
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3033-8. PubMed ID: 8768870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fifteen years of GH replacement improves body composition and cardiovascular risk factors.
    Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2013 May; 168(5):745-53. PubMed ID: 23428613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults.
    Rodríguez-Arnao J; Jabbar A; Fulcher K; Besser GM; Ross RJ
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):53-60. PubMed ID: 10468965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults.
    al-Shoumer KA; Gray R; Anyaoku V; Hughes C; Beshyah S; Richmond W; Johnston DG
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):795-802. PubMed ID: 9713570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline characteristics and effects of growth hormone therapy over two years in younger and elderly adults with adult onset GH deficiency.
    Franco C; Johannsson G; Bengtsson BA; Svensson J
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4408-14. PubMed ID: 16940452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.
    Diazzi C; Brigante G; Ferrannini G; Ansaloni A; Zirilli L; De Santis MC; Zona S; Guaraldi G; Rochira V
    Endocrine; 2017 Mar; 55(3):885-898. PubMed ID: 27730472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of a Bioelectrical Impedance Device against the Reference Method Dual Energy X-Ray Absorptiometry and Anthropometry for the Evaluation of Body Composition in Adults.
    Day K; Kwok A; Evans A; Mata F; Verdejo-Garcia A; Hart K; Ward LC; Truby H
    Nutrients; 2018 Oct; 10(10):. PubMed ID: 30308974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial.
    Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
    Eur J Endocrinol; 2004 Sep; 151(3):343-50. PubMed ID: 15362963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two years of replacement therapy in adults with growth hormone deficiency.
    Verhelst J; Abs R; Vandeweghe M; Mockel J; Legros JJ; Copinschi G; Mahler C; Velkeniers B; Vanhaelst L; Van Aelst A; De Rijdt D; Stevenaert A; Beckers A
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):485-94. PubMed ID: 9404448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
    Attanasio AF; Bates PC; Ho KK; Webb SM; Ross RJ; Strasburger CJ; Bouillon R; Crowe B; Selander K; Valle D; Lamberts SW;
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1600-6. PubMed ID: 11932289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
    Newman CB; Frisch KA; Rosenzweig B; Roubenoff R; Rey M; Kidder T; Kong Y; Pursnani A; Sedlis SP; Schwartzbard A; Kleinberg DL
    J Clin Endocrinol Metab; 2011 Jan; 96(1):122-32. PubMed ID: 20926529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy.
    Orme SM; Sebastian JP; Oldroyd B; Stewart SP; Grant PJ; Stickland MH; Smith MA; Belchetz PE
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):453-9. PubMed ID: 1486696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.